Gilead and partner Galapagos no longer will pursue clinical trials in the United States with filgotinib in rheumatoid arthritis and other conditions, but still could pursue the drug as a treatment for inflammatory bowel disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,